# Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults

> **NCT04783311** · PHASE1,PHASE2 · COMPLETED · sponsor: **EuBiologics Co.,Ltd** · enrollment: 279 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** EuCorVac-19
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT04783311
- **Lead sponsor:** EuBiologics Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-23
- **Primary completion:** 2021-10-15
- **Final completion:** 2022-09-27
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2023-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04783311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04783311, "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04783311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*